Literature DB >> 17195147

Hypothermia for the treatment of neonatal ischemic encephalopathy: is the genie out of the bottle?

Tara R Lang1, Tyler K M Hartman, Susan R Hintz, Christopher E Colby.   

Abstract

Evidence suggests that hypothermia for hypoxic ischemic encephalopathy in the term neonate may decrease the risk of death or neurodevelopmental impairment. The objective of this study was to determine how hypothermia has been incorporated into practice. An anonymous survey was sent to medical directors of United States neonatal intensive care units (NICUs) in October 2005. We received completed surveys from 441 (54.5%) of 809 of NICUs. Only 6.4% of respondents used hypothermia. The most common method was total body cooling (64.3%) compared with head cooling (25%) or both (10.7%). At centers that did not offer hypothermia, 29% transferred infants to an institution that did. Centers that offered hypothermia were more likely at academic institutions (76.9%) compared with private practices (11.5%; p < 0.001). Hypothermia was more likely offered at institutions that offered extracorporeal membrane oxygenation (ECMO; 57%) than centers where ECMO was not offered (43%; p < 0.001). There has not been widespread use of hypothermia. There are a variety of protocols used. As results of further outcome studies become available, educational efforts and national practice guidelines will be essential.

Entities:  

Mesh:

Year:  2006        PMID: 17195147     DOI: 10.1055/s-2006-958157

Source DB:  PubMed          Journal:  Am J Perinatol        ISSN: 0735-1631            Impact factor:   1.862


  2 in total

1.  Hypothermia for newborns with hypoxic ischemic encephalopathy.

Authors:  Abraham Peliowski-Davidovich
Journal:  Paediatr Child Health       Date:  2012-01       Impact factor: 2.253

2.  Successful hypothermia treatment of hypoxic-ischemic encephalopathy in a neonate with epidermolysis bullosa.

Authors:  Nilgun Karadag; Serdar Beken; Dilek Dilli; Aysegul Zenciroglu; Nurullah Okumus
Journal:  Indian J Pediatr       Date:  2013-08-11       Impact factor: 1.967

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.